NASDAQ: ICUI
Icu Medical Inc Stock

$136.14-4.23 (-3.01%)
Updated Jun 22, 2026
ICUI Price
$136.14
Fair Value Price
$180.15
Market Cap
$3.40B
52 Week Low
$107.00
52 Week High
$160.29
P/E
72.8x
P/B
1.61x
P/S
1.48x
PEG
0.93x
Dividend Yield
N/A
Revenue
$2.16B
Earnings
$46.34M
Gross Margin
37.9%
Operating Margin
4.03%
Profit Margin
2.1%
Debt to Equity
0.9
Operating Cash Flow
$167M
Beta
1.02
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A

ICUI Overview

ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ICUI's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
B
ICUI
Ranked
#7 of 41

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$8.92A
$21.75B
$14.93B
View Top Medical Stocks

Be the first to know about important ICUI news, forecast changes, insider trades & much more!

ICUI News

Overview

Due Diligence Score

Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ICUI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ICUI ($136.14) is undervalued by 24.43% relative to our estimate of its Fair Value price of $180.15 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ICUI ($136.14) is significantly undervalued by 24.43% relative to our estimate of its Fair Value price of $180.15 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ICUI ($136.14) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ICUI due diligence checks available for Premium users.

Valuation

ICUI fair value

Fair Value of ICUI stock based on Discounted Cash Flow (DCF)

Price
$136.14
Fair Value
$180.15
Undervalued by
24.43%
ICUI ($136.14) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ICUI ($136.14) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ICUI ($136.14) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ICUI price to earnings (PE)

For valuing profitable companies with steady earnings

Company
72.8x
Industry
43.04x
Market
7.94x
ICUI is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ICUI is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation

ICUI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.61x
Industry
3.11x
ICUI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ICUI price to earnings growth (PEG)

For valuing profitable companies with growth potential

ICUI is good value based... subscribe to Premium to read more.
PEG Value Valuation

ICUI's financial health

Profit margin

Revenue
$530.2M
Net Income
$30.1M
Profit Margin
5.7%
ICUI's Earnings (EBIT) of $86.99M... subscribe to Premium to read more.
Interest Coverage Financials
ICUI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$4.0B
Liabilities
$1.9B
Debt to equity
0.9
ICUI's short-term assets ($1.21B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ICUI's long-term liabilities ($1.38B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ICUI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ICUI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$38.9M
Investing
-$11.2M
Financing
-$44.1M
ICUI's operating cash flow ($167.43M)... subscribe to Premium to read more.
Debt Coverage Financials

ICUI vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ICUIB$3.40B-3.01%72.80x1.61x
WRBYC$3.31B+3.97%1,349.50x8.81x
HAEB$3.30B-2.21%35.21x4.14x
MMSIB$3.97B-1.07%28.30x2.44x
NVSTB$4.15B-1.54%60.74x1.35x

Icu Medical Stock FAQ

What is Icu Medical's quote symbol?

(NASDAQ: ICUI) Icu Medical trades on the NASDAQ under the ticker symbol ICUI. Icu Medical stock quotes can also be displayed as NASDAQ: ICUI.

If you're new to stock investing, here's how to buy Icu Medical stock.

What is the 52 week high and low for Icu Medical (NASDAQ: ICUI)?

(NASDAQ: ICUI) Icu Medical's 52-week high was $160.29, and its 52-week low was $107.00. It is currently -15.07% from its 52-week high and 27.23% from its 52-week low.

How much is Icu Medical stock worth today?

(NASDAQ: ICUI) Icu Medical currently has 24,993,585 outstanding shares. With Icu Medical stock trading at $136.14 per share, the total value of Icu Medical stock (market capitalization) is $3.40B.

Icu Medical stock was originally listed at a price of $8.25 in Dec 31, 1997. If you had invested in Icu Medical stock at $8.25, your return over the last 28 years would have been 1,549.58%, for an annualized return of 10.53% (not including any dividends or dividend reinvestments).

How much is Icu Medical's stock price per share?

(NASDAQ: ICUI) Icu Medical stock price per share is $136.14 today (as of Jun 22, 2026).

What is Icu Medical's Market Cap?

(NASDAQ: ICUI) Icu Medical's market cap is $3.40B, as of Jun 23, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Icu Medical's market cap is calculated by multiplying ICUI's current stock price of $136.14 by ICUI's total outstanding shares of 24,993,585.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.